Published in Expert Opin Drug Saf on January 25, 2011
Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer (2012) 1.20
Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis. Onco Targets Ther (2016) 0.88
Prospects in folate receptor-targeted radionuclide therapy. Front Oncol (2013) 0.83
Revisiting cutaneous adverse reactions to pemetrexed. Oncol Lett (2011) 0.79
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). Invest New Drugs (2013) 0.76
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health Qual Life Outcomes (2013) 0.75
The evolving role of the pathologist in the management of lung cancer. Lung Cancer Manag (2015) 0.75
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
NF-kappaB and virus infection: who controls whom. EMBO J (2003) 2.08
Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer. Oncology (Williston Park) (2010) 2.06
Compliance with therapy in hypertensive patients. Intern Emerg Med (2006) 1.66
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Transcription of Satellite III non-coding RNAs is a general stress response in human cells. Nucleic Acids Res (2007) 1.58
Comparative genome analysis of Trichophyton rubrum and related dermatophytes reveals candidate genes involved in infection. MBio (2012) 1.55
Treating advanced non-small cell lung cancer in the elderly. Ther Adv Med Oncol (2010) 1.53
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer (2003) 1.44
A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype. Hum Mol Genet (2005) 1.43
The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist (2008) 1.39
Treatment of pulmonary neuroendocrine tumours: state of the art and future developments. Cancer Treat Rev (2012) 1.37
Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem (2006) 1.33
Treatment of advanced non small cell lung cancer. J Thorac Dis (2011) 1.32
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol (2008) 1.30
Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis (2006) 1.27
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. Cancer Biol Ther (2013) 1.26
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Recent developments of targeted therapies in the treatment of non-small cell lung cancer. Curr Drug Discov Technol (2009) 1.26
Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol (2010) 1.23
Herpes simplex virus disrupts NF-kappaB regulation by blocking its recruitment on the IkappaBalpha promoter and directing the factor on viral genes. J Biol Chem (2006) 1.22
The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. Oncologist (2007) 1.20
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation (2007) 1.19
Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem (2007) 1.18
Phenotypic features of carbohydrate sulfotransferase 3 (CHST3) deficiency in 24 patients: congenital dislocations and vertebral changes as principal diagnostic features. Am J Med Genet A (2010) 1.17
Congenital joint dislocations caused by carbohydrate sulfotransferase 3 deficiency in recessive Larsen syndrome and humero-spinal dysostosis. Am J Hum Genet (2008) 1.15
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist (2007) 1.14
Chondrodysplasia and abnormal joint development associated with mutations in IMPAD1, encoding the Golgi-resident nucleotide phosphatase, gPAPP. Am J Hum Genet (2011) 1.12
Antifungal resistance mechanisms in dermatophytes. Mycopathologia (2008) 1.10
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis (2010) 1.09
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.07
Treatment of advanced non-small-cell lung cancer in the elderly. Lung Cancer (2009) 1.07
Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer (2009) 1.07
Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene (2003) 1.06
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist (2009) 1.05
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer (2010) 1.03
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol (2013) 1.02
Differential expression of both extracellular and intracellular proteins is involved in the lethal or nonlethal phenotypic variation of BrtlIV, a murine model for osteogenesis imperfecta. Proteomics (2007) 1.01
Interaction of decorin with CNBr peptides from collagens I and II. Evidence for multiple binding sites and essential lysyl residues in collagen. Eur J Biochem (2002) 1.01
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy. Stem Cells (2012) 1.00
Lung cancer in the elderly. J Clin Oncol (2007) 1.00
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol (2007) 0.99
Molecular diagnosis of analbuminemia: a novel mutation identified in two Amerindian and two Turkish families. Clin Chem (2002) 0.99
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist (2009) 0.99
Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist (2009) 0.97
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol (2008) 0.96
The pH signaling transcription factor PacC mediates the growth of Trichophyton rubrum on human nail in vitro. Med Mycol (2006) 0.94
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci (2005) 0.94
Medical treatment of small cell lung cancer: state of the art and new development. Expert Opin Pharmacother (2013) 0.94
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol (2007) 0.93
Defective proteoglycan sulfation of the growth plate zones causes reduced chondrocyte proliferation via an altered Indian hedgehog signalling. Matrix Biol (2010) 0.92
A novel splicing mutation causes an undescribed type of analbuminemia. Biochim Biophys Acta (2002) 0.90
Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Anticancer Res (2009) 0.90
Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer? Lung Cancer (2009) 0.90
A transcript finishing initiative for closing gaps in the human transcriptome. Genome Res (2004) 0.89
Further delineation of CANT1 phenotypic spectrum and demonstration of its role in proteoglycan synthesis. Hum Mutat (2012) 0.89
Treatment of small cell lung cancer in the elderly. Oncologist (2005) 0.89
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer (2010) 0.88
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res (2010) 0.88
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs (2010) 0.88
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer (2005) 0.88
Self-aggregation of fibrillar collagens I and II involves lysine side chains. Micron (2006) 0.88